Chandarlapaty, Sarat

Publications

Sort by

Co-Author Network

selected publications

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. Cancer cell. 2024 Academic Article GET IT
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. 2024 GET IT
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer. 2024 GET IT
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer. European journal of cancer. 2024 Academic Article GET IT
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms. Cancer research. 2024 Academic Article GET IT
Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer. NPJ precision oncology. 2024 Academic Article GET IT
RB1 genetic alterations in estrogen receptor-positive breast carcinomas: Correlation with neuroendocrine differentiation. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2024 Academic Article GET IT
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer. 2024 GET IT
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer. 2024 GET IT
APOBEC3 mutagenesis drives therapy resistance in breast cancer. 2024 GET IT
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation. Annals of oncology : official journal of the European Society for Medical Oncology. 2024 Review GET IT
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. The Lancet. Oncology. 2024 Review GET IT
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nature reviews. Clinical oncology. 2024 Review GET IT
ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer discovery. 2023 Academic Article GET IT
Non-Lobular Invasive Breast Carcinomas with Bi-Allelic Pathogenic CDH1 Somatic Alterations: a Histologic, Immunophenotypic and Genomic Characterization. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2023 Academic Article GET IT
Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation. The Journal of clinical investigation. 2023 Academic Article GET IT
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis. NPJ breast cancer. 2023 Academic Article GET IT
Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell reports. 2023 Academic Article GET IT
A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer. Cancer research communications. 2023 Academic Article GET IT
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Emerging Therapies for Breast Cancer. Cold Spring Harbor perspectives in medicine. 2023 Review GET IT
Times cited: 8
Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nature reviews. Cancer. 2023 Review GET IT
Rise of Antibody-Drug Conjugates: The Present and Future. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2023 Academic Article GET IT
ADCs or: How I Learned to Stop Worrying and Love Chemotherapy. Cancer discovery. 2023 Editorial Article GET IT
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. Annals of oncology : official journal of the European Society for Medical Oncology. 2022 Academic Article GET IT
Times cited: 26
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance. NPJ breast cancer. 2022 Academic Article GET IT
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nature communications. 2022 Academic Article GET IT
Times cited: 33
PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry. Cancer discovery. 2022 Academic Article GET IT
Accelerating drug development in breast cancer: New frontiers for ER inhibition. Cancer treatment reviews. 2022 Review GET IT
Times cited: 13
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. Cancer research. 2022 Academic Article GET IT
Times cited: 6
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 28
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 39
Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. The Journal of pathology. 2022 Academic Article GET IT
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. NPJ breast cancer. 2022 Academic Article GET IT
Times cited: 13
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022 Academic Article GET IT
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature communications. 2021 Academic Article GET IT
Times cited: 52
Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. JCI insight. 2021 Academic Article GET IT
Times cited: 13
Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2021 Academic Article GET IT
Times cited: 14
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer discovery. 2021 Academic Article GET IT
Times cited: 82
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature communications. 2021 Academic Article GET IT
Times cited: 91
Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. Molecular cancer research : MCR. 2021 Academic Article GET IT
Times cited: 9
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 20
Independent real-world application of a clinical-grade automated prostate cancer detection system. The Journal of pathology. 2021 Academic Article GET IT
Times cited: 87
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ breast cancer. 2021 Academic Article GET IT
Times cited: 19
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. NPJ breast cancer. 2021 Academic Article GET IT
Times cited: 19
Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. The Journal of molecular diagnostics : JMD. 2021 Academic Article GET IT
Times cited: 25
Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors. Cancer research. 2021 Academic Article GET IT
Times cited: 24
Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Molecular cell. 2021 Academic Article GET IT
Times cited: 72
Unlocking the potential of antibody-drug conjugates for cancer therapy. Nature reviews. Clinical oncology. 2021 Review GET IT
Times cited: 633
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. JCO precision oncology. 2021 Academic Article GET IT
Times cited: 5
Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis. The Journal of clinical investigation. 2021 Academic Article GET IT
Times cited: 25
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling. Molecular cancer research : MCR. 2020 Academic Article GET IT
Times cited: 11
Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. The journal of pathology. Clinical research. 2020 Academic Article GET IT
Times cited: 4
Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. Journal of clinical pathology. 2020 Academic Article GET IT
Times cited: 12
The genomic landscape of metastatic histologic special types of invasive breast cancer. NPJ breast cancer. 2020 Academic Article GET IT
Times cited: 27
Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. 2020 GET IT
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome medicine. 2020 Academic Article GET IT
Times cited: 15
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 15
Head-to-Head Evaluation of ¹⁸F-FES and ¹⁸F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2020 Academic Article GET IT
Times cited: 87
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹Zr-Pertuzumab PET/CT. Radiology. 2020 Academic Article GET IT
Times cited: 45
Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas. Histopathology. 2020 Academic Article GET IT
Times cited: 26
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 21
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 ^E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 71
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature cancer. 2020 Academic Article GET IT
Times cited: 104
Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA oncology. 2020 Academic Article GET IT
Times cited: 79
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer discovery. 2019 Academic Article GET IT
Times cited: 90
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science (New York, N.Y.). 2019 Academic Article GET IT
Times cited: 197
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI cancer spectrum. 2019 Academic Article GET IT
Times cited: 19
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI cancer spectrum. 2019 Academic Article GET IT
Times cited: 13
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. Journal of medicinal chemistry. 2019 Academic Article GET IT
Times cited: 143
Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Breast cancer research : BCR. 2019 Academic Article GET IT
Times cited: 44
Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Editorial Article GET IT
Times cited: 18
Reversible histone glycation is associated with disease-related changes in chromatin architecture. Nature communications. 2019 Academic Article GET IT
Times cited: 133
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. The oncologist. 2019 Academic Article GET IT
Times cited: 9
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer cell. 2018 Academic Article GET IT
Times cited: 318
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. eLife. 2018 Academic Article GET IT
Times cited: 72
Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. ACS chemical biology. 2018 Academic Article GET IT
Times cited: 7
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 66
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science signaling. 2018 Academic Article GET IT
Times cited: 59
Publisher Correction: Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. 2018 GET IT
Times cited: 2
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer cell. 2018 Academic Article GET IT
Times cited: 653
Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2018 Academic Article GET IT
Times cited: 15
Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study. Journal of vascular and interventional radiology : JVIR. 2018 Academic Article GET IT
Times cited: 12
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. ACS medicinal chemistry letters. 2018 Academic Article GET IT
Times cited: 49
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nature reviews. Cancer. 2018 Review GET IT
Times cited: 146
Incorporating Biology Into Breast Cancer Staging: American Joint Committee on Cancer, Eighth Edition, Revisions and Beyond. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2018 Review GET IT
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. Oncogene. 2018 Academic Article GET IT
Times cited: 95
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature communications. 2018 Academic Article GET IT
Times cited: 114
Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial. Cancer. 2018 Academic Article GET IT
Times cited: 79
ESR1 and endocrine therapy resistance: more than just mutations. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Editorial Article GET IT
Times cited: 10
Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 252
Genomic profiling of ER⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science translational medicine. 2017 Academic Article GET IT
Times cited: 92
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast cancer research : BCR. 2017 Academic Article GET IT
Times cited: 49
OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 1720
AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 235
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology. 2017 Academic Article GET IT
Times cited: 68
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR⁺, HER2^- advanced breast cancer: results from BOLERO-2. British journal of cancer. 2017 Academic Article GET IT
Times cited: 115
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer discovery. 2016 Academic Article GET IT
Times cited: 281
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2016 Academic Article GET IT
Times cited: 287
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA oncology. 2016 Academic Article GET IT
Times cited: 386
Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer research. 2016 Academic Article GET IT
Times cited: 40
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer cell. 2016 Academic Article GET IT
Times cited: 176
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 32
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 150
Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 61
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. eLife. 2016 Academic Article GET IT
Times cited: 218
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 10
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Science translational medicine. 2015 Academic Article GET IT
Times cited: 452
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nature genetics. 2015 Academic Article GET IT
Times cited: 140
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science translational medicine. 2015 Academic Article GET IT
Times cited: 272
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer cell. 2014 Academic Article GET IT
Times cited: 203
PTEN is a protein tyrosine phosphatase for IRS1. Nature structural & molecular biology. 2014 Academic Article GET IT
Times cited: 101
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 43
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer discovery. 2014 Academic Article GET IT
Times cited: 156
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 69
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast cancer research : BCR. 2013 Academic Article GET IT
Times cited: 85
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature genetics. 2013 Academic Article GET IT
Times cited: 936
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer cell. 2012 Academic Article GET IT
Times cited: 445
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 180
Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer discovery. 2012 Information Resource GET IT
Times cited: 176
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 4
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer discovery. 2011 Academic Article GET IT
Times cited: 371
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer cell. 2011 Academic Article GET IT
Times cited: 995
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 315
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 271
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert review of anticancer therapy. 2011 Information Resource GET IT
Times cited: 390
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011 Academic Article GET IT
Times cited: 448
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell. 2011 Academic Article GET IT
Times cited: 824
Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Applied immunohistochemistry & molecular morphology : AIMM. 2010 Academic Article GET IT
Times cited: 52
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 123
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 2009 Academic Article GET IT
Times cited: 104
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PloS one. 2008 Academic Article GET IT
Times cited: 250
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer research. 2008 Academic Article GET IT
Times cited: 160
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 166
Ash1, a daughter cell-specific protein, is required for pseudohyphal growth of Saccharomyces cerevisiae. Molecular and cellular biology. 1998 Academic Article GET IT
Times cited: 60

more ...

less ...

Background

education and training

M.D., Wake Forest University School of Medicine 2002
Ph.D., University of North Carolina 1998
B.S., College of William and Mary 1993

Contact

full name

Sarat Chandarlapaty

primary email

chandars@mskcc.org

VIVO Weill Cornell Medical College

Sarat Chandarlapaty Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email